scispace - formally typeset
P

Paquita Nurden

Researcher at Centre national de la recherche scientifique

Publications -  60
Citations -  3714

Paquita Nurden is an academic researcher from Centre national de la recherche scientifique. The author has contributed to research in topics: Platelet & Platelet activation. The author has an hindex of 27, co-authored 60 publications receiving 3529 citations. Previous affiliations of Paquita Nurden include University of Würzburg & French Alternative Energies and Atomic Energy Commission.

Papers
More filters
Journal ArticleDOI

Identification of the platelet ADP receptor targeted by antithrombotic drugs.

TL;DR: The cloning of this receptor, designated P2Y12, is described and evidence that a patient with a bleeding disorder has a defect in this gene is provided, which should facilitate the development of better antiplatelet agents to treat cardiovascular diseases.
Journal ArticleDOI

Recommendations for the standardization of light transmission aggregometry : a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH

TL;DR: The Platelet Physiology Subcommittee of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis formed a working party of experts with the aim of producing a series of consensus recommendations for standardizing LTA, which formed the basis of a consensus document, which is the subject of the present report.
Journal ArticleDOI

An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function.

TL;DR: A patient (M.L.) with an inherited bleeding disorder whose specific feature is that ADP induces a limited and rapidly reversible platelet aggregation even at high doses is described.
Journal ArticleDOI

Clopidogrel: a review of its mechanism of action.

TL;DR: Clopidogrel not only constitutes a potent antithrombotic drug in humans but also a good tool to study the effect of ADP on platelets.
Journal ArticleDOI

Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures.

TL;DR: Recombinant factor VIIa was used as first-line therapy in 3 patients with Glanzmann's thrombasthenia and anti-GPIIb-IIIa iso-antibodies who were scheduled for invasive procedures and resulted in excellent clinical efficacy and tolerance in 2 cases.